Molecular nanoparticle-based gene delivery systems

Purpose: Nonviral gene delivery lacks molecularly well-defined carriers suitable for rigorous structure–activity relationship (SAR) studies. Viral vectors raise immunogenicity, cost, and cargo-size concerns, while polymers, dendrimers, and cationic lipids are often polydisperse or supramolecularly ill-defined. The review argues that “molecular nanoparticles” (MNPs)—monodisperse, shape-persistent molecular entities—can provide programmable, single-isomer gene delivery platforms.

Hypothesis: No formal experimental hypothesis. Central thesis: precisely defined MNP scaffolds bearing cationic and hydrophobic functionalities can supramolecularly complex nucleic acids and mediate safe, efficient delivery, enabling SAR-driven optimization of nonviral vectors.

Aims: Review advances in MNP-based nucleic acid delivery. - Cover cyclodextrin, calixarene, pillarene, fullerene, cyclopeptide, and cyclotrehalan platforms. - Emphasize how molecular definition enables structure/activity/self-assembly studies. - Highlight potential for safe delivery of pDNA, siRNA, and mRNA to target cells.

Delivery system: Scaffolds: cyclodextrins (α, β, γ), calix[n]arenes, pillar[n]arenes, fullerene C60, cyclic peptides, cyclotrehalans. - Functional elements: cationic heads (amines, oligoethyleneamine, guanidines, histidine, arginine/lysine clusters), hydrophobic tails (alkyl chains), thiourea/amide linkers, PEG, targeting ligands. - Payloads: plasmid DNA (pDNA), siRNA, mRNA. - Targeting/auxiliary ligands: mannose, galactose, folate, anisamide, rabies virus glycoprotein, adamantane host–guest modules. - Nanocomplex types: CDplexes, calixplexes, CTplexes, peptide/DNA or siRNA complexes.

Approach: Review of in vitro and in vivo literature. Model systems include COS-7, HeLa, HepG2, BNL-CL2, RAW 264.7, RD-4, MCF-7, MDA-MB-231, PC-3, LNCaP, Calu-3, N2a, HEK-293, and others. In vivo examples include systemic mouse injection, Huntington’s disease mouse model, acute colitis model, prostate tumor targeting, and a pilot aerosol/vaginal pig study. Payloads include luciferase, IL-12, GFP, HTT siRNA, TNF-α siRNA, and MRP1 siRNA.

Key methods: Physicochemical characterization: DLS, TEM, AFM, SAXS, circular dichroism. - Nucleic acid binding: gel electrophoresis, ethidium bromide displacement, ITC, SPR. - Cellular studies: confocal microscopy, flow cytometry, luciferase reporter assays, MTT toxicity. - In vivo readouts: luminescence imaging, organ distribution, gene expression, disease-model endpoints.

Key results: Optimized polycationic amphiphilic cyclodextrins (e.g., 5 and 6) formed 80–100 nm CDplexes at N/P >2 and mediated transfection comparable to or better than PEI/Lipofectamine LTX in COS-7, HeLa, HepG2, and BNL-CL2 cells. - Mannosylated pacD 8 selectively transfected RAW 264.7 macrophages via the mannose receptor. - Guanidinium calix[4]arene 25 formed <100 nm pDNA nanocomplexes with full protection and transfection in RD-4 cells; arginine-cluster calixarene 31 outperformed Lipofectamine LTX/PEI across several cell lines. - Cationic fullerene TPFE mediated in vivo insulin gene delivery in mice, increasing insulin and reducing blood glucose, with no acute liver/kidney toxicity versus Lipofectamine LTX. - Cyclopeptide 44 achieved PEI-comparable transfection in HeLa/HEK-293 cells with better cytotoxicity profile and non-endocytic uptake. - Cyclotrehalan paCTs mediated transfection comparable to branched PEI in COS-7/HepG2 cells without toxicity; in vivo expression mainly in liver and lung.

Interpretation: The authors conclude that molecularly well-defined MNP platforms enable precise pre-organization of functional elements and reliable SAR studies, offering a promising route toward safer, programmable nonviral gene delivery systems. They argue that collecting SAR data on monodisperse architectures is necessary to advance the field beyond current trial-and-error vector design.

Limitations: Review article; no primary experimental data. - Most MNP vectors show in vitro efficacy; in vivo validation remains limited. - Transfection efficiency still generally below viral vectors. - Endosomal escape, intracellular trafficking, and mucosal barriers remain unresolved; some uptake routes are nonproductive. - Synthetic complexity and limited clinical translation; no large-animal or clinical data beyond pilot studies.